Gen-Probe Reports Financial Results for Second Qu...((non-GAAP) (non-GAAP) (GAAP) ...),Health

Date:7/30/2009

(non-GAAP) (non-GAAP) (GAAP) (GAAP) ---------- -------- ----- ----- Total revenues $490 to $503 $490 to $510 $490 to $503 $490 to $510 million million million million Product gross margins 68% to 69% 68% to 70% 68% to 69% 68% to 70% Acquisition-related intangibles amortization N/A N/A $3-4 million N/A R&D expenses ~ 22% 21% to 23% ~ 22% 21% to 23% Marketing and sales expenses 10% to 11% 10% to 11% 10% to 11% 11% to 12% G&A expenses 10% to 11% 10% to 11% 11% to 12% 11% to 12% Tax rate ~ 34% 33% to 34% ~ 34% 33% to 34% Diluted shares ~ 52 million ~ 52 million ~ 52 million ~ 52 million EPS $1.85 to $1.95 $1.85 to $2.00 $1.73 to $1.85 $1.72 to $1.90

Webcast Conference Call

A live webcast of Gen-Probe's second quarter 2009 conference call for investors can be accessed athttp://www.gen-probe.com beginning at 4:30 p.m. Eastern Time today. The webcast will be archived for at least 90 days. A telephone replay of the call also will be available for approximately 24 hours. The replay number is 800-879-6754 for domestic callers or 402-220-5334 for international callers.

About Gen-Probe

Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective NATs that are used primarily to diagnose human diseases and screen donated human blood. Gen-Probe has more than 25 years of NAT expertise, and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT
'/>"/>

SOURCE Gen-Probe Incorporated Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
Related medicine news :

1. Gen-Probe to Webcast Two Upcoming Investor Presentations
2. Gen-Probe Reports Financial Results for First Quarter 2009
3. Gen-Probe, Roche Prevail in Arbitration With Digene Concerning Human Papillomavirus Agreement
4. Gen-Probe Board of Directors Elects Carl Hull Chief Executive Officer
5. Tepnel Shareholders Approve Acquisition by Gen-Probe
6. Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008
7. Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash
8. Gen-Probe and Novartis Agree to Extend and Expand Blood Screening Collaboration
9. Eric Tardif Joins Gen-Probe as Senior Vice President, Corporate Strategy
10. Gen-Probe to Webcast Presentation at the 27th Annual J.P. Morgan Healthcare Conference
11. Gen-Probe to Webcast Presentation at the 20th Annual Piper Jaffray Health Care Conference